Cyted Health, a leading gastrointestinal molecular diagnostics company, has secured $44 million in Series B financing to accelerate its commercial expansion in the United States. The round was led by EQT Life Sciences through its EQT Health Economics strategy and co-led by Advent Life Sciences and British Business Bank, with continued support from existing investors Morningside and BGF.
The Cambridge University-founded company is pioneering minimally invasive cell collection coupled with proprietary biomarker discovery to transform the detection of pre-cancerous, cancerous and inflammatory esophageal conditions. The funding will support commercial expansion of Cyted's diagnostics platform in the US, consolidate existing success across the UK, and expand its portfolio of advanced diagnostic tests.
Proven Clinical Impact in UK Market
Cyted's technology has demonstrated significant success across the UK's National Health Service, completing over 35,000 tests and building a robust portfolio of peer-reviewed publications proving patient acceptability and real-world clinical impact. The company's existing platform consists of EndoSign, an FDA 510(k)-cleared device enabling minimally invasive collection of esophageal cells, and advanced biomarker molecular testing for esophageal condition detection.
Esophageal cancer represents a critical unmet medical need, considered one of the deadliest cancers globally with survival rates ranging from 20-25% according to available data. This poor prognosis underscores the importance of earlier detection technologies like Cyted's platform.
US Market Expansion Strategy
Cyted has already established a presence in the US market with a registered address in Wilmington, Delaware, and partner laboratory facilities in Atlanta, Georgia. The company recently launched the DETECT-ME clinical validation study across 18 US sites, which has been enrolling patients since March 2025. This study aims to validate clinical performance of Cyted's newest assays and molecular tests for detecting esophageal conditions using EndoSign.
"This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting esophageal diseases earlier," said Marcel Gehrung, CEO and Co-founder of Cyted Health. "This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio."
Investor Confidence in Platform Innovation
Bruno Holthof, Partner at EQT Life Sciences, commented: "Cyted is strongly positioned to redefine the standard of care in upper GI diagnostics worldwide. Its minimally invasive diagnostics platform is the standout innovation to capture this significant market opportunity, and we're delighted to add the company to our portfolio."
Kaasim Mahmood, General Partner at Advent Life Sciences, added: "Cyted has demonstrated a rare combination of clinical innovation, patient-centered delivery, and commercial execution with an impressive foundation in the UK. We're proud to support its next phase of growth."
Government Support for Life Sciences Innovation
UK Science Minister Lord Vallance expressed support for the company's growth, stating: "I am pleased to see the British Business Bank back Cyted – a company whose growth demonstrates the ability of our universities to turn world-class life sciences research into successful commercial opportunities with the potential to improve people's lives. Life sciences form a critical part of this Government's ambitions for both the economy and healthcare – and through our Life Sciences Sector Plan, we will continue to support the industry to even greater success."
Carmine Circelli, Director, Life Sciences at British Business Bank, noted: "Cyted is an excellent example of the kind of high-impact business we aim to back. Their innovation has the potential to transform early cancer detection and create lasting health outcomes both in the UK and globally."
